Trinity Biotech Secures $25M Financing to Fuel Growth and Innovation
Event summary
- Trinity Biotech has secured a $25 million Standby Equity Purchase Agreement with Yorkville Advisors Global, valid for up to 36 months.
- The financing will support commercialization efforts and R&D programs, including the CGM+ continuous glucose monitoring platform.
- Trinity Biotech reported $48.6 million in revenues for the trailing 12 months ended September 30, 2025.
- The company's recent commercial momentum has been driven by renewed demand for HIV testing products, including Uni-Gold and TrinScreen.
The big picture
Trinity Biotech's $25 million financing deal underscores its strategic focus on expanding commercialization activities and advancing its innovation agenda. The move comes as the company seeks to capitalize on renewed demand for HIV testing products and develop next-generation diabetes management solutions. The financing provides flexibility to access capital as market conditions permit, reflecting the company's cautious yet ambitious growth strategy in the competitive biotechnology sector.
What we're watching
- Execution Risk
- How Trinity Biotech will balance commercialization efforts with high-potential R&D programs, particularly the CGM+ platform.
- Market Dynamics
- Whether the company can sustain its recent commercial momentum in HIV testing amid potential fluctuations in global demand.
- Innovation Pace
- The pace at which Trinity Biotech can advance its other innovations, including Epicapture cancer monitoring and the Metabolomics biomarker-based platform.
Related topics